The Push for New COVID-19 Vaccines Amid Safety Concerns and Low Case Rates
The FDA’s vaccine advisory committee unanimously recommended a monovalent JN.1-lineage COVID-19 vaccine for the 2024-2025 formula despite low COVID-19 hospitalization...
The FDA’s vaccine advisory committee unanimously recommended a monovalent JN.1-lineage COVID-19 vaccine for the 2024-2025 formula despite low COVID-19 hospitalization...